Two versus three doses of COVID-19 vaccine and post-vaccination COVID-19 infection in hemodialysis patients

IF 1.8 Q3 INFECTIOUS DISEASES
Laila A. Ahmed , Hayam H. Mansour , Salwa I. Elshennawy , Marwa A.A. Ramadan , Mohamed A.M. Kamal , Soso S. Mohamed , Omaima Mohamed Ali , Amal H. Ibrhim
{"title":"Two versus three doses of COVID-19 vaccine and post-vaccination COVID-19 infection in hemodialysis patients","authors":"Laila A. Ahmed ,&nbsp;Hayam H. Mansour ,&nbsp;Salwa I. Elshennawy ,&nbsp;Marwa A.A. Ramadan ,&nbsp;Mohamed A.M. Kamal ,&nbsp;Soso S. Mohamed ,&nbsp;Omaima Mohamed Ali ,&nbsp;Amal H. Ibrhim","doi":"10.1016/j.infpip.2024.100338","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aim</h3><p>Patients with chronic kidney disease including those undergoing hemodialysis (HD) constitute a particularly challenging group regarding COVID-19 vaccination. The present study aimed to compare the rate of reinfection after two and three doses of Sinopharm COVID-19 vaccine in HD patients.</p></div><div><h3>Patients and methods</h3><p>The study included 80 HD patients who received three doses of Sinopharm COVID-19 vaccine. In addition, there were another 80 patients who received only two doses of the vaccine. Patients in the latter group were selected based on propensity matching score with 1:1 ratio. Patients were monitored for post-vaccination COVID-19 infection using PCR examination of nasopharyngeal swabs. Patients were also monitored for post-vaccination complications including general complaints (headache, fever, fatigue), injection site complaints (arm pain, swelling, itching, rash), musculoskeletal complaints (muscle spasm or pain, joint pain) and others. All patients were followed for six months.</p></div><div><h3>Results</h3><p>The present study included 80 patients submitted to COVID-19 vaccination with two doses of Sinopharm vaccine (GI) and other 80 patients who received three doses of the same vaccine (GII). At the end of follow up, 11 patients (13.8 %) in GI caught COVID-19 infection. In contrast, no patient in GII had infection (<em>P</em>&lt;0.001). Comparison between patients who had COVID-19 infection and those without infection revealed that the former subgroup had significantly lower BMI (23.3 ± 2.3 versus 27.5 ± 8.1 Kg/m<sup>2</sup>), higher frequency of associated Hepatitis C (HCV) infection (54.6 % versus 2.9 %, <em>P</em>&lt;0.001) and higher serum ferritin levels [median (IQR): 1101.0 (836.0–1564.0) versus 675.0 (467.0–767.7) ng/mL, <em>P</em>=0.01]. Binary logistic regression analysis identified high serum ferritin levels [OR (95% CI): 0.014 (0.001–0.15), <em>P</em>&lt;0.001] and associated HCV infection [OR (95% CI): 0.99 (0.98–1.01), <em>P</em>=0.02] as significant predictors of post-vaccination COVID-19 infection in multivariate analysis.</p></div><div><h3>Conclusions</h3><p>A three dose regime of Sinopharm COVID-19 vaccine associated with significantly lower rate of reinfection COVID-19 infection in HD patients. Infected patients had significantly lower BMI, higher frequency of HCV and higher ferritin levels.</p></div>","PeriodicalId":33492,"journal":{"name":"Infection Prevention in Practice","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590088924000027/pdfft?md5=96ab4ad641406aa02c1464b7728e9189&pid=1-s2.0-S2590088924000027-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection Prevention in Practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590088924000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim

Patients with chronic kidney disease including those undergoing hemodialysis (HD) constitute a particularly challenging group regarding COVID-19 vaccination. The present study aimed to compare the rate of reinfection after two and three doses of Sinopharm COVID-19 vaccine in HD patients.

Patients and methods

The study included 80 HD patients who received three doses of Sinopharm COVID-19 vaccine. In addition, there were another 80 patients who received only two doses of the vaccine. Patients in the latter group were selected based on propensity matching score with 1:1 ratio. Patients were monitored for post-vaccination COVID-19 infection using PCR examination of nasopharyngeal swabs. Patients were also monitored for post-vaccination complications including general complaints (headache, fever, fatigue), injection site complaints (arm pain, swelling, itching, rash), musculoskeletal complaints (muscle spasm or pain, joint pain) and others. All patients were followed for six months.

Results

The present study included 80 patients submitted to COVID-19 vaccination with two doses of Sinopharm vaccine (GI) and other 80 patients who received three doses of the same vaccine (GII). At the end of follow up, 11 patients (13.8 %) in GI caught COVID-19 infection. In contrast, no patient in GII had infection (P<0.001). Comparison between patients who had COVID-19 infection and those without infection revealed that the former subgroup had significantly lower BMI (23.3 ± 2.3 versus 27.5 ± 8.1 Kg/m2), higher frequency of associated Hepatitis C (HCV) infection (54.6 % versus 2.9 %, P<0.001) and higher serum ferritin levels [median (IQR): 1101.0 (836.0–1564.0) versus 675.0 (467.0–767.7) ng/mL, P=0.01]. Binary logistic regression analysis identified high serum ferritin levels [OR (95% CI): 0.014 (0.001–0.15), P<0.001] and associated HCV infection [OR (95% CI): 0.99 (0.98–1.01), P=0.02] as significant predictors of post-vaccination COVID-19 infection in multivariate analysis.

Conclusions

A three dose regime of Sinopharm COVID-19 vaccine associated with significantly lower rate of reinfection COVID-19 infection in HD patients. Infected patients had significantly lower BMI, higher frequency of HCV and higher ferritin levels.

血液透析患者接种两剂或三剂 COVID-19 疫苗与接种后 COVID-19 感染倾向得分匹配分析
背景和目的慢性肾脏病患者,包括接受血液透析(HD)的患者,是COVID-19疫苗接种方面一个特别具有挑战性的群体。本研究旨在比较 HD 患者接种两剂和三剂国药集团 COVID-19 疫苗后的再感染率。此外,还有 80 名患者只接种了两剂疫苗。后一组患者按照 1:1 的比例进行倾向匹配。通过对鼻咽拭子进行 PCR 检测,监测患者接种 COVID-19 疫苗后的感染情况。此外,还监测患者接种疫苗后的并发症,包括全身不适(头痛、发热、乏力)、注射部位不适(手臂疼痛、肿胀、瘙痒、皮疹)、肌肉骨骼不适(肌肉痉挛或疼痛、关节疼痛)等。本研究包括 80 名接种了两剂国药集团 COVID-19 疫苗(GI)的患者和另外 80 名接种了三剂相同疫苗(GII)的患者。在随访结束时,接种GI疫苗的11名患者(13.8%)感染了COVID-19。相比之下,GII 没有患者感染(P<0.001)。对感染 COVID-19 和未感染 COVID-19 的患者进行比较后发现,前者的体重指数(BMI)明显低于后者(23.3 ± 2.3 对 27.5 ± 8.1 Kg/m2),伴有丙型肝炎(HCV)感染的频率更高(54.6 % 对 2.9 %,P<0.001),血清铁蛋白水平更高[中位数(IQR):1101.0(836.0-1564.0)对 675.0(467.0-767.7)纳克/毫升,P=0.01]。二元逻辑回归分析发现,在多变量分析中,高血清铁蛋白水平[OR(95% CI):0.014 (0.001-0.15),P<0.001]和相关的HCV感染[OR(95% CI):0.99 (0.98-1.01),P=0.02]是接种COVID-19疫苗后感染的重要预测因素。受感染患者的体重指数(BMI)明显较低,HCV感染率较高,铁蛋白水平较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infection Prevention in Practice
Infection Prevention in Practice Medicine-Public Health, Environmental and Occupational Health
CiteScore
4.80
自引率
0.00%
发文量
58
审稿时长
61 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信